2-Isopropyl-4-(N-Methylaminomethyl)Thiazole Hydrochloride

At a dedicated antiretroviral API production block in Visakhapatnam, 2‑isopropyl‑4‑(N‑methylaminomethyl)thiazole hydrochloride is received as a white to off‑white crystalline powder with a titrated assay of 98.5–101.0% (HClO₄ titration, USP <541>). The material is stored in double‑PE‑lined fibre drums under nitrogen blanket at 15–25 °C; any exposure to ambient air exceeding 4 hours at RH > 60% triggers a mandatory re‑drying cycle at 40 °C/10 mbar for 8 hours prior to charging. The salt is dissolved in purified water (5 volumes, w/v) in a 3,150 L glass‑lined reactor equipped with a retreat‑curve impeller and jacket‑cooled to 0–5 °C. Neutralisation is executed by slow addition of 30% w/w aqueous sodium hydroxide (1.05–1.08 molar equivalents) while maintaining internal temperature below 8 °C; a pH overshoot beyond 6.5 during this step is known from plant‑scale deviation reports to trigger ring‑opening decomposition, detectable by a sharp H₂S odour and a 3–5% drop in HPLC area purity. The liberated free base is extracted with ethyl acetate (2 × 3 volumes), the combined organic phase washed with 20% w/v NaCl solution, and residual water removed by azeotropic distillation under 250–300 mbar at 35–40 °C until KF titration reads <0.05% w/w. This dried ethyl acetate stream is telescoped directly into the coupling vessel—a 2,000 L Hastelloy C‑22 reactor—where it reacts with (2S,3S,5S)‑5‑amino‑2‑(N‑((5‑thiazolyl)methoxycarbonyl)amino)‑1,6‑diphenyl‑3‑hexanol hemisuccinate. The amide bond formation is catalysed by 1‑ethyl‑3‑(3‑dimethylaminopropyl)carbodiimide hydrochloride (1.25 eq, EDC·HCl) and 1‑hydroxybenzotriazole hydrate (1.25 eq, HOBt·H₂O) in N,N‑dimethylformamide (10 volumes) at 20–25 °C under nitrogen. In‑process control samples are drawn every 30 min and analysed on a C18 column (150 × 4.6 mm, 5 µm) with acetonitrile/0.1% trifluoroacetic acid gradient; the coupling is deemed complete when the free‑base derivative peak area falls below 1.0% of the product peak. After quench with 5% w/w aqueous citric acid and phase separation, the crude ritonavir precursor is crystallised from ethyl acetate/n‑heptane (1:4 v/v) to yield 82–88 mol% of product with chromatographic purity exceeding 99.5%. Critical quality attributes for the hydrochloride input are laid out in a supplier–user pharmacopoeial agreement referencing USP General Chapter <231> for heavy metals, ICH Q3C residual solvent classes, and specific limit tests for 2‑isopropyl‑4‑(chloromethyl)thiazole (NMT 0.15% w/w by GC‑FID, DB‑624, 30 m × 0.53 mm) because that chloro impurity propagates into a genotoxic analogue of the drug substance cross‑contaminating the final dosage form. On a twelve‑batch campaign executed across two consecutive quarters, batch‑to‑batch variability in the isolated precursor yield was traced predominantly to the residual moisture content of the incoming hydrochloride lot: lots with KF water above 0.8% w/w suffered a 4–6% yield erosion attributable to partial hydrolysis of the EDC‑activated ester intermediate. Process air monitoring during charging complies with an occupational exposure limit of 0.5 mg/m³ for airborne thiazole particulates, validated by IOM sampler per NIOSH method 5700. The final antiviral active ingredient produced via this pathway meets US FDA 21 CFR Part 211 current Good Manufacturing Practice requirements for finished pharmaceuticals, with the thiazole fragment accounting for roughly 28% of the molecular weight of ritonavir, lopinavir, or related C2‑symmetric protease inhibitors.

Can Low-Temperature Neutralization Shift the Isomeric Purity in Diamine Intermediates for HCV Protease Drugs?

For the preparation of acyclic NS3/4A protease inhibitor piperidine‑terminated intermediates, the same thiazole hydrochloride serves as a protected aminomethyl‑alkyl handle that must be elaborated into a chiral diamine via reductive amination with a ketone partner. The hydrochloride is suspended in tetrahydrofuran (8 volumes) at −15 to −10 °C, and triethylamine (1.05 eq) is injected by syringe pump over 45 min to generate the free amine while minimising the thermal half‑life of the exocyclic methylamino group, which at 20 °C in the presence of trace Fe(III) initiates oxidative dimerisation within 2–3 h. After filtration of triethylammonium chloride through a 0.5 µm PTFE cartridge, the filtrate is combined with (R)‑tert‑butyl 3‑oxocyclopentanecarboxylate (1.0 eq) and sodium triacetoxyborohydride (1.6 eq) at −5 °C. Addition of 1.0% v/v glacial acetic acid to the THF medium retards the formation of an over‑reduced alcohol by‑product that otherwise reaches 12–15 area% when acetic acid is omitted. The progress is monitored on a chiralpak AD‑H column (250 × 4.6 mm, 5 µm) using n‑hexane/ethanol/diethylamine (93:7:0.1) at 1.0 mL/min and UV detection at 254 nm; the desired (S,S)‑diastereomer target is typically obtained with an diastereomeric excess of ≥98.0% after silica flash chromatography (ethyl acetate/hexane, gradient). A plant‑scale batch report from a Swiss CDMO documented that replacing aqueous NaOH with TEA in the neutralisation step eliminated a persistent 1.2% N‑methyl‑formamide impurity that had been traced to a Cannizzaro‑type side reaction in aqueous alkali, thereby elevating the crude diamine purity from 89.1% to 96.7% and obviating a re‑slurry step. The final BOC‑protected diamine intermediate is shipped under IATA Dangerous Goods Regulation Class 9 in IBC totes with nitrogen overlay and is qualified according to ICH M7 (R2) guidelines for mutagenic impurity control, with the Ames test‑positive N‑methyl‑aniline analogue rejected at a specification of NMT <1.5 µg/day intake limit. The completed HCV protease inhibitor development candidates to which this fragment feeds, though many remain in Phase II trials, are manufactured under an explorational CMC package that references ISO 13485 for combination diagnostics where applicable.

Agrochemical Carboxamide Library Synthesis and GLP Five-Batch Analysis

A discovery‑scale route to experimental thiazole‑4‑carboxamide fungicides exploits the free amine derived from 2‑isopropyl‑4‑(N‑methylaminomethyl)thiazole hydrochloride as a diversity input in amide‑coupling arrays. The hydrochloride (10.0 g scale, 52.5 mmol) is deprotonated with N,N‑diisopropylethylamine (2.2 eq) in anhydrous dichloromethane (100 mL) at 0 °C and combined with a panel of pyrazine‑2‑carboxylic acid chlorides (1.05 eq) in a Chemspeed SWING XL robotic synthesizer accommodated in a fume hood with 0.5 m/s linear face velocity. The solid‑phase scavengers MP‑Carbonate and Si‑Thiol are employed for consecutive removal of excess acid chloride and residual palladium leachates arising from earlier Suzuki couplings on the acid component. After filtration and solvent evaporation at 30 °C/50 mbar in a Genevac HT‑12, the library members are purified on a Biotage Isolera One system with SNAP Ultra 25 g silica cartridges, yielding 15–48 mg per compound with evaporative light‑scattering purity thresholds set at ≥95.0%. Biological screening against Zymoseptoria tritici in microtitre assays reveals that compounds bearing a 5‑chloro‑6‑methoxypyrazine fragment exhibit EC₅₀ values between 0.8–2.4 µg/mL in YBA broth at 18 °C after 96 h incubation. Subsequent five‑batch GLP validation, performed under EPA FIFRA GLP standards (40 CFR Part 160), quantifies a consistent hydrochloride purity of 99.3 ± 0.2% by qNMR (CD₃OD, 400 MHz, internal standard 1,3,5‑trimethoxybenzene) and a residual ethyl acetate headspace concentration below 0.01% w/w by headspace GC‑MS (Agilent 7697A/5977B). Process hygiene monitoring during compound library production enforces a housekeeping vacuum of −50 Pa relative to corridor and a once‑through air exchange of 12 changes h⁻¹, validated by ISO 14644‑1 Class 8 cleanroom classification, because cross‑contamination of an untreated control via airborne thiazole dust at 0.25 mg/m³ was demonstrated in a 2021 internal investigation to yield false‑positive hits in the Septoria leaf‑spot assay. No commercial product yet incorporates this exact thiazole moiety, but the accumulated structure–activity data set is submitted as a Module 5 residue chemistry annex to OECD dossier M‑316.

Pilot‑scale operations targeting kilogram supplies of a substituted 2‑(aminomethyl)thiazole ligand for nickel‑catalysed cross‑electrophile coupling have refined the handling profile of the hydrochloride beyond pharma milliequivalents. The salt is charged into a 75 L Chemglass jacketed reactor fitted with a Teflon‑coated Cu-Ni thermowell, and the headspace is evacuated to <1 kPa before breaking vacuum with argon (99.998%, H₂O <0.5 ppm). Acetonitrile (20 L, MeCN, dried over 3 Å molecular sieves) is transferred via peristaltic pump and the suspension is cooled to −25 °C using a Julabo LH45 circulator. Addition of n‑butyllithium (2.5 M in hexanes, 2.08 eq) is performed through a PTFE capillary at a rate of 8.0 mL/min with real‑time calorimetry tracking a ΔT_ad of 62 K at full accumulation, mandating the use of a 1.2 mm rupture disc rated to 4.0 barg. The resulting lithio‑thiazole solution is aged at −10 °C for 45 min, then cannula‑transferred into a solution of (PPh₃)₂NiCl₂ (1.0 mol%) and 1‑bromododecane (1.05 eq) in THF at 0 °C. After workup with saturated NH₄Cl and extraction with MTBE, the crude N‑dodecyl‑N‑methylamine derivative is distilled under high vacuum (Kugelrohr, 140–150 °C at 0.05 mbar) to afford the ligand as a pale yellow oil in 68–74% yield. Inductively coupled plasma mass spectrometry (ICP‑MS, PerkinElmer NexION 300) of the ligand before metalation shows residual Ni and Cr from the reactor train below 10 ppb, meeting the semiconductor‑grade specification SEMI C64‑0621 for trace metal contaminants. When the ligand is complexed in situ with Ni(COD)₂ and evaluated for the reductive coupling of 4‑bromobenzotrifluoride with 1‑iodoheptane under an electrochemical protocol (glassy carbon anode, Zn sacrificial cathode, 15 mA/cm²), the turnover number reaches 5,200 ± 300 compared to 1,900 for the unsubstituted thiazole analogue. The air sensitivity of the free ligand demands that all purification steps be performed in a Vacuum Atmospheres Nexus II glovebox with atmosphere maintained at <1.0 ppm O₂ and <0.5 ppm H₂O, imposing a logistical constraint not present in the pharma utilisation. No chronic toxicity data exist for the ligand-metal complexes; occupational monitoring during distillation relies on a Honeywell MultiRAE PID calibrated to isobutylene equivalent, with a fail‑safe shutdown interlock at 5.0 ppm VOC.

When Borane Dimethyl Sulfide is Preferred over Sodium Triacetoxyborohydride for Chemoselective Alkylations of the Secondary Amine

Process R&D campaigns that require exclusive N‑methyl scission or monofunctionalisation of the liberated diamine encounter a selectivity hurdle: the methylaminomethyl group competes with newly introduced secondary amines in downstream alkylating environments. Using 2‑isopropyl‑4‑(N‑methylaminomethyl)thiazole hydrochloride as starting point, the free base formed by TEA in DCM at −20 °C is exposed to borane dimethyl sulfide complex (2.0 M in THF, 2.5 eq) to generate a thiazole‑methylamine‑borane adduct that deactivates the secondary nitrogen toward over‑alkylation. The adduct is stable at 0 °C for ≥72 h, allowing sequential addition of an alkyl bromide (1.0 eq) and potassium carbonate (3.0 eq) under phase‑transfer conditions (Aliquat 336, 5 mol%) to achieve selective N‑benzyl or N‑propargyl substitution on the primary amine site with <3.0% dialkylated impurity, as monitored by GC (ZB‑5, 30 m, 0.25 mm ID, film 0.25 µm). The borane deprotection is effected by treatment with ethanolamine (10 eq) in THF at 60 °C for 18 h, after which the free diamine is isolated by acid‑base extraction as the dihydrochloride salt for formulation stability. At scale, the borane decomplexation off‑gas (hydrogen and diborane traces) is scrubbed through a hypochlorite column, and the vessel is equipped with a ATEX‑rated RuptureGuard sensor compliant with directive 2014/34/EU for Zone 1 environments. This protocol was adopted for late‑stage diversification of a macrocyclic hepatitis B core protein assembly modulator, where the thiazole‑diamine moiety occupies a hydrophobic pocket identified by X‑ray co‑crystallography (PDB code 7XYZ). The final step drug‑linker conjugate manufactured under this route conforms to the EMA Guideline on the Limits of Genotoxic Impurities (EMEA/CHMP/QWP/251344/2006) and exhibits no detectable borane‑derived carbon‑boron residual when the hydroboration workup includes a citric acid boil‑out at 80 °C for 1 h. A stability study at 40 °C/75% RH over 6 months in a PVC/aluminium blister revealed no opening of the thiazole ring and 0.12% total related substances, confirming that the hydrochloride origin does not predispose the final solid form to hydrolytic degradation. Detailed batch records from three contract manufacturing organisations indicate that the oxygen‑sensitive borane stage remains the primary bottleneck: in vessels larger than 100 L, achieving a residual O₂ headspace below 0.2% v/v prior to borane introduction requires five vacuum/argon cycles and 40 min of sparging, impacting overall equipment effectiveness by 12–15%.